Product image of Comirnaty Jn.1 (Bretovameran) supplied by GNH India

Comirnaty Jn.1

Active Ingredient:
Bretovameran
Origin:
EU

Comirnaty Jn.1 (Bretovameran)

Comirnaty Jn.1 is a COVID-19 vaccine developed by BioNTech Manufacturing GmbH. It is designed to help prevent COVID-19 by stimulating the immune system.

Manufacturer / TM Owner

Biontech Manufacturing Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Comirnaty Jn.1 is used to provide protection against COVID-19. It is administered intramuscularly and is intended for use in individuals as recommended by healthcare providers. The vaccine aims to reduce the risk of severe illness, hospitalization, and death due to COVID-19.

Side Effects

  • Common effects of Comirnaty Jn.1 may include mild to moderate reactions at the injection site, such as pain, redness, or swelling. Some individuals may also experience temporary systemic effects like fatigue, headache, muscle pain, chills, or fever. These effects are generally short-lived and resolve within a few days.

Precautions & Warnings

  • Comirnaty Jn.1 should be administered by healthcare professionals. Individuals with a history of severe allergic reactions to any component of the vaccine should consult their healthcare provider before receiving it. It is important to follow storage and handling instructions to maintain the vaccine's efficacy.

Avoid Interactions

  • There are no specific drug interactions widely reported for Comirnaty Jn.1. However, individuals should inform their healthcare provider about any medications they are taking to ensure safe administration. As with any vaccine, it is advisable to avoid alcohol and other substances that may affect the immune system.

Frequently Asked Questions

Comirnaty Jn.1 is used to help prevent COVID-19 by stimulating the immune system to produce a protective response.

Comirnaty Jn.1 is administered intramuscularly, typically in the upper arm, by a healthcare professional.

Common effects may include pain, redness, or swelling at the injection site, as well as temporary systemic effects like fatigue, headache, or fever.

Individuals with a history of severe allergic reactions to any component of the vaccine should consult their healthcare provider before receiving it.

There are no specific drug interactions widely reported, but it is advisable to inform your healthcare provider about any medications you are taking.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Bretovameran

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT